The Latest Breaking News from Verrica Pharmaceuticals

Verrica Pharmaceuticals Q1 Earnings Call Highlights

Verrica Pharmaceuticals (NASDAQ:VRCA) reported higher first-quarter revenue and record demand for its molluscum contagiosum treatment YCANTH, while outlining progress on late-stage development programs in common warts and basal cell carcinoma. President and Chief Executive Officer Jayson Rieger sai

MarketBeat · May 13

Verrica Holds Type A Meeting With FDA For Potential Approval Of Skin Infection Candidate

The U.S. Food and Drug Administration (FDA) convened a Type A meeting with Verrica Pharmaceuticals (NASDAQ: VRCA) regarding the course of action for the clearance of its drug candidate VP-102.

Benzinga · Jun 28, 2022

Analyst Ratings for Verrica Pharmaceuticals

Within the last quarter, Verrica Pharmaceuticals (NASDAQ:VRCA) has observed the following analyst ratings:

Benzinga · May 31, 2022